The indicators and questions in this document are designed for use by national AIDS programmes and partners to assess the state of a country’s HIV and AIDS response, and to measure progress towards achieving national HIV targets. Countries are encouraged to integrate these indicators and questions into their ongoing monitoring efforts and to report comprehensive national data through the Global AIDS Monitoring (GAM) process.
Infection prevention and control consists of evidence-based measures intended to prevent exposure and reduce the risk of transmission of infectious agents.
Infection prevention and control activities are amongst the key components envisaged by the End TB Strategy to curb the tuberculosis (TB) burden worldwide. The WHO operational handbook on tuberculosis.
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing the risk of HIV acquisition.
This guidelines is an updated version of the pervious “National Consolidated Guidelines on Strategic Information of HIV Response in Nepal 2016-2021”. This guidelines has been updated to serve for monitoring the priorities set by NHSP 2021-2026 and is inline with international and national strategies and plans. With restructuring of the country, the SI system should also address all three tiers of health governanace. This guidelines has aimed to become a hands-on document, with organizational/project system and other emerging issues incorporated.
The objective of the guidelines is to provide updated, evidence-informed clinical and practical recommendations on case management of people with symptoms of STI. The national guidelines recommend a syndromic approach for the management of the STI.
This global progress in identification of newer drug molecules that are more robust and less toxic, a significant reduction in the cost of therapy and innovative approaches to service delivery and increasing access to treatment have literally transformed the disease from a virtual death sentence in the early 1980s to a chronic manageable disease now.
Hepatitis C virus (HCV) infection is a major public health problem and cause of chronic liver disease that leads to approximately 399 000 deaths annually. In 2019, only 21% of the 58 million persons with chronic HCV infection had been diagnosed, and 13%, treated.
These guidelines provide updated evidence-based recommendations on the priority HCV-related topics from the 2018 WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection and the 2017 WHO Guidelines on hepatitis B and C testing.
National Guideline on HIV testing and treatment 2022 introduces new standards for viral load testing and viral load suppression. The guidelines also stress on community-based care of PLHIV with differentiated care approach which means less hospital visits for healthy PLHIV and more time to provide for critical patients.
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of bedaquiline and delamanid in young children with multidrug- and rifampicin-resistant TB and decentralized and family-centred, integrated models of care for TB case detection and prevention in children and adolescents.
